Avedro is a commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Co.'s proprietary Avedro Corneal Remodeling Platform is comprised of its KXL and Mosaic systems, each of which delivers ultraviolet A light, and a suite of proprietary single-use riboflavin drug formulations, which, when applied together to the cornea, induce a biochemical reaction called corneal collagen cross-linking. Co.'s KXL system in combination with its Photrexa drug formulations is indicated for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. The AVDR stock yearly return is shown above.
The yearly return on the AVDR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AVDR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|